June 2026 in “Dove Medical Press (Taylor and Francis Group)” JAK inhibitors show promise for treating alopecia areata, but long-term safety and emotional support are important.
April 2026 in “Antibodies” The role of antibodies in alopecia is unclear, but JAK inhibitors show promise for treatment.
February 2026 in “Journal of the American Academy of Dermatology” Ophiasis mainly affects females, lasts longer, and has lower regrowth rates, with a new classification system helping predict treatment response.
February 2026 in “Journal of Dermatological Treatment” CG2001 is safe and well-tolerated for treating hair loss, with fewer side effects than oral finasteride.
January 2026 in “Medicina” JAK inhibitors show promise for treating various skin disorders effectively and safely.
December 2025 in “Cosmetics” New treatments for alopecia show promise in restoring hair growth by targeting immune and hormonal factors.
December 2025 in “Actas Dermo-Sifiliográficas” Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.
High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.
November 2025 in “International Journal of Molecular Sciences” Combining different drugs can improve hair loss treatment.
August 2025 in “American Journal of Dermatopathology” Accurate diagnosis and personalized treatment are crucial in dermatopathology.